

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: November 23, 2009 <i>(use as many sheets as necessary)</i>				Application Number	10/706,328
				Filing Date	11/12/2003
				First Named Inventor	Alison Hannah
				Art Unit	1614
				Examiner Name	James D. Anderson
Sheet	1	of	4	Attorney Docket Number	072121-0366

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US-2002/0165218	11-07-2002	HALBROOK ET AL.	
		US-2004/0002518	01-01-2004	RENHOWE ET AL.	
		US-2004/0006101	01-08-2004	RENHOWE ET AL.	
		US-2004/0097545	05-20-2004	RENHOWE ET AL.	
		US-2004/0220196	11-04-2004	HANNAH ET AL.	
		US-2005/0054672	03-10-2005	RENHOWE ET AL.	
		US-2005/0137399	06-23-2005	CAI ET AL.	
		US-2005/0203101	09-15-2005	BARSANTI ET AL.	
		US-2005/0256157	11-17-2005	GESNER ET AL.	
		US-4,882,342	11-21-1989	VON DER SAAL ET AL.	
		US-5,330,992	07-19-1994	EISSENSTAT ET AL.	
		US-5,480,883	01-02-1996	SPADA ET AL.	
		US-6,593,344	07-15-2003	BIEDERMANN ET AL.	
		US-6,756,383	06-29-2004	RENHOWE ET AL.	
		US-6,759,417	07-06-2004	RENHOWE ET AL.	
		US-7,064,215	06-20-2006	RENHOWE ET AL.	
		US-7,179,912	02-20-2007	HALBROOK ET AL.	
		US-7,470,709	12-30-2008	BARSANTI ET AL.	

UNPUBLISHED U.S. PATENT APPLICATION DOCUMENTS					
Examiner Initials*	Cite No. ¹	U.S. Patent Application Document	Filing Date of Cited Document MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Serial Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
		WO-00/11709	03-02-2000	KLONINKLIJKE PHILIPS ELECTRONICS N.V.		
		WO-00/35492	06-22-2000	DU PONT PHARMACEUTICALS COMPANY		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: November 23, 2009 <i>(use as many sheets as necessary)</i>				Application Number	10/706,328
				Filing Date	11/12/2003
				First Named Inventor	Alison Hannah
				Art Unit	1614
				Examiner Name	James D. Anderson
Sheet	2	of	4	Attorney Docket Number	072121-0366

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ² Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		WO-01/52875	07-26-2001	LUDWIG INSTITUTE FOR CANCER RESEARCH		
		WO-01/53268	07-26-2001	AGOURON PHARMACEUTICALS, INC.		
		WO-2004/063170	07-29-2004	UNIVERSITY OF DELHI		
		WO-2005/009967	02-03-2005	JANSSEN PHARMACEUTICA, N.V.		
		WO-2005/046590	05-26-2005	CHIRON CORPORATION		
		WO-2005/047244	05-26-2005	CHIRON CORPORATION		
		WO-2006/081445	08-03-2006	CHIRON CORPORATION		
		WO-2006/127926	11-30-2006	NOVARTIS AG		
		WO-91/04974 (English abstract attached)	04-18-1991	BOEHRINGER MANNHEIM GMBH		
		WO-99/16755	04-08-1999	MERCK & CO., INC.		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		BERWANGER, B. et al., "Loss of a FYN-regulated differentiation and growth arrest pathway in advanced stage neuroblastoma," Cancer Cell, Vol. 2, November 2002, pp. 377-386; published by Cell Press.	
		CAIRA, Mino R., "Crystalline polymorphism of Organic Compounds," Topics in Current Chemistry, Vol. 198, Springer Verlag, 1998.	
		European Partial Search Report for EP 07011978 dated September 19, 2007.	
		European Supplementary Search Report for EP 03746614.1 dated May 24, 2007.	
		International Preliminary Examination Report for PCT/US03/10463 dated June 8, 2004.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: November 23, 2009 <i>(use as many sheets as necessary)</i>		Application Number	10/706,328
		Filing Date	11/12/2003
		First Named Inventor	Alison Hannah
		Art Unit	1614
		Examiner Name	James D. Anderson
Sheet	3	of	4
		Attorney Docket Number	072121-0366

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		International Search Report for PCT/US00/13420 dated August 14, 2000.	
		International Search Report for PCT/US01/42131 dated March 6, 2002.	
		International Search Report for PCT/US03/10463 dated June 12, 2003.	
		JOHNSON et al., "Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials," British Journal of Cancer, Vol. 84, No. 10, 2001, pp. 1424-1431.	
		LEE, S. H. et al., "In vivo Target Modulation and Biological Activity of CHIR-258, a Multitargeted Growth Factor Receptor Kinase Inhibitor, in Colon Cancer Models," Clin. Cancer Res., May 15, 2005, Vol. 11, No. 10; pp. 3633-3641.	
		LOPES DE MENEZES, D. E. et al., "CHIR-258: A Potent Inhibitor of FLT3 Kinase in Experimental Tumor Xenograft Models of Human Acute Myelogenous Leukemia," Clin. Cancer Res., July 15, 2005, Vol. 11, No. 14, pp. 5281-5291.	
		MAJOLINI, M. B. et al., "Dysregulation of the Protein Tyrosine Kinase LCK in Lymphoproliferative Disorders and in Other Neoplasias," Leukemia and Lymphoma, Vol. 35(3-4), 1999, pp. 245-254; published by OPA (Overseas Publishers Association) N.V.	
		MUNDY, "Preclinical models of bone metastases," Semin. Oncol., 28(4 Suppl. 11), 2001, pp. 2-8.	
		SIEMEISTER, G. et al., "Two Independent Mechanisms Essential for Tumor Angiogenesis: Inhibition of Human Melanoma Xenograft Growth by Interfering with either the Vascular Endothelial Growth Factor Receptor Pathway or the Tie-2 Pathway," Cancer Research, Vol. 59, July 1, 1999, pp. 3185-3191.	
		SUGGITT et al., "50 Years of Preclinical Anticancer Drug Screening: Empirical to Target-Driven Approaches," Clinical Cancer Research, Vol. 11, 2005, pp. 971-981.	
		SUSA, M. et al., "Src inhibitors: drugs for the treatment of osteoporosis, cancer or both?," TiPS, Vol. 21, December 2000, pp. 489-495; published by Elsevier Science Ltd.	
		Taiwanese Search Report in Application No. 92131830 received July 24, 2009 (English translation only).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: November 23, 2009 <i>(use as many sheets as necessary)</i>				Application Number	10/706,328
				Filing Date	11/12/2003
				First Named Inventor	Alison Hannah
				Art Unit	1614
				Examiner Name	James D. Anderson
Sheet	4	of	4	Attorney Docket Number	072121-0366

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		TRUDEL, S. et al., "CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma," Blood, 1 April 2005, Vol. 105, No. 7, pp. 2941-2948.	
		VALTOLA, R. et al., "VEGFR-3 and Its Ligand VEGF-C Are Associated with Angiogenesis in Breast Cancer," American Journal of Pathology, Vol. 154, No. 5, May 1999, pp. 1381-1390; published by American Society for Investigative Pathology.	

Examiner Signature		Date Considered	
-------------------------------	--	----------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.